

**Remarks**

Claims 1-46 were pending. By this amendment, claims 1, 8 and 46 are cancelled. No new claims are added. Therefore, claims 2-7 and 9-45 are now pending.

By this amendment the specification has been updated to reflect prior related applications, to include reference to sequence identifiers, and to insert the abstract on a separate page. The sequence listing was amended to include the corresponding PCT application.

Claim 2 has been amended to be an independent claim.


Claims 2-7, 9-41 and 44-45 were amended to comply with U.S. practice. For example, claims 2-7, 9-41 and 44-45 were amended to correct antecedent basis. Claims 2-5, 16, 18, 20, 21, 30, 32, and 44 were amended to include reference to sequence identifiers. Claims 16 and 20-42 were amended to change the use to claims to method claims.

Claims 8 and 46 were cancelled, and their language introduced into claims 7 and 45, respectively. Claims 5, 6, 9, 11, 18, 22, 23, 25, 27, 28, 37, 39, 40, 42, and 45 were amended to remove multiple dependencies.

No new matter has been added by this amendment.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446